High dose CHOP: A phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351

References

• McKelvey E M, Gottlieb J A, Wilson H E, Haut A, Talley R W, Stephens R, Lane M, et al. Hydroxydaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484–1493
   PubMed Web of Science ®Google Scholar
• Fisher R, Gaynor E, Dahlberg S, Oken M, Grogan T, Mize E, Glick J, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Fisher R I, Miller T P, Dana B W, Jones S E, Dahlberg S, Coltman C, Jr. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Semin Hematol 1987; 24(Suppl 1)21–25
   PubMed Web of Science ®Google Scholar
• Gordon L I, Harrington D, Andersen J, Colgan J, Glick J, Neiman R, et al. Comparison of a second-generation chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1342–1349
   PubMed Web of Science ®Google Scholar
• Klimo P, Connors J. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102: 596–602
   PubMed Web of Science ®Google Scholar
• Longo D L, DeVita V T, Jr, Duffey P L, Wesley M N, Ihde D C, Hubbard S M, et al. Superiority of ProMACE-CytaBom over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol 1991; 9: 25–38
   PubMed Web of Science ®Google Scholar
• Skarin A, Canellos G, Rosenthal D, Case D, Jr, MacIntyre J, Pinkus G, et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1983; 1: 91–98
   PubMed Web of Science ®Google Scholar
• Frei E, Canellos G P. Dose: a critical factor in cancer chemotherapy. Am J Med 1980; 69: 585–594
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielimi C, Hagenbeek A, Somers R, van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Shipp M, Abeloff M, Antman K, Carroll G, Hagenbeek A, Loeffler M, et al. International Consensus Conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 1999; 17: 423–429
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, Coiffier B, Bosly A, Tilly H, et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1994; 12: 2543–2551
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol – a Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 2000; 18: 3025–3030
   PubMed Web of Science ®Google Scholar
• Kaiser U, Uebelacker I, Abel U, Birkman J, Trumper L, Schmalenberg H, et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for ‘aggressive’ lymphoma. J Clin Oncol 2002; 20: 4413–4419
   PubMed Web of Science ®Google Scholar
• Martelli M, Gherlinzoni F, De Renzo A, Zinzani P, De Vivo A, Cantonetti M, et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol 2003; 21: 1255–1262
   PubMed Web of Science ®Google Scholar
• Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287–1295
   PubMed Web of Science ®Google Scholar
• Santini G, Salvagno L, Leoni P, Chisesi T, De Souza C, Sertoli M R, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16: 2796–2802
   PubMed Web of Science ®Google Scholar
• Doorduijn J, van der Holt B, van Imhoff G, Van der Hem K, Kramer M, van Oers M, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphomas. J Clin Oncol 2003; 21: 3041–3050
   PubMed Web of Science ®Google Scholar
• Itoh K, Ohtsu T, Wakita H, Igarashi T, Ishizawa K, Onozawa Y, et al. Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma. Ann Oncol 2000; 11: 1241–1247
   PubMed Web of Science ®Google Scholar
• Meyer R, Gyger M, Langley R, Lesperance B, Caplan S. A phase I trial of standard and cyclophosphamide dose-escalated CHOP with granulocyte colony stimulating factor in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 1998; 30: 591–600
   PubMed Web of Science ®Google Scholar
• Portlock C S, Qin J, Schaindlin P, Roistacher N, Myers J, Filippa D, et al. The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide. Ann Oncol 2004; 15: 1495–1503
   PubMed Web of Science ®Google Scholar
• Santoro A, Balzarotti M, Tondini C, Zanini M, Giardini R, Latteri F, et al. Dose-escalation of CHOP in non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 519–525
   PubMed Web of Science ®Google Scholar
• Shipp M, Neuberg D, Janicek M, Canellos G P, Shulman L. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. J Clin Oncol 1995; 13: 2916–2923
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Jaffee E S, Harris N L, Stein H, Vardiman J W. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon 2001
   Google Scholar
• Bartlett N L, Petroni G R, Parker B A, Wagner N, Gockerman J, Omura G, et al. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOEP) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854. Cancer 2001; 92: 207–217
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphomas. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117–4126
   PubMed Web of Science ®Google Scholar
• Habermann T M, Weller E A, Morrison V A, Cassileth P A, Cohn J B, Dakhil S R, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121–3127
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379–391
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller A, Rube C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634–641
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller A, Rudolph B, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104: 626–633
   PubMed Web of Science ®Google Scholar
• Blayney D, LeBlanc M, Grogan T, Gaynor E, Chapman R, Spiridonidis C, et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 2003; 21: 2466–2473
   PubMed Web of Science ®Google Scholar
• Itoh K, Ohtsu T, Fukuda H, Sasaki Y, Ogura M, Morishima Y, et al. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505. Ann Oncol 2002; 13: 1347–1355
   PubMed Web of Science ®Google Scholar
• Balzarotti M, Spina M, Sarina B, Magagnoli M, Castagna L, Milan I, et al. Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubucin and cyclophosphamide. Ann Oncol 2002; 13: 1341–1346
   PubMed Web of Science ®Google Scholar
• Armitage J, Carbone P, Connors J, Levine A, Bennett J, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003; 21: 897–906
   PubMed Web of Science ®Google Scholar
• Greene M, Young R, Merrill J, DeVita V T. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Res 1983; 43: 1891–1898
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Ersboll J, Sorensen H, Keiding N, Larsen S, Philip P, et al. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas: comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med 1985; 103: 195–200
   PubMed Web of Science ®Google Scholar
• Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102: 4284–4289
   PubMed Web of Science ®Google Scholar
• Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927–1932
   PubMed Web of Science ®Google Scholar
• Wilson W, Grossbard M, Pittaluga S, Cole D, Pearson D, Drbohlav N, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002; 99: 2685–2693
   PubMed Web of Science ®Google Scholar
• Monti S, Savage K, Kutok J, Feuerhake F, Kurtin P, Mihm M, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105: 1851–1861
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan W, Connors J, Campo E, Fisher R, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947
   PubMed Web of Science ®Google Scholar